Latest news with #VigilNeuroscienceInc
Business Insider
25-05-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL), Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF) and Viridian Therapeutics (VRDN)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vigil Neuroscience Inc (VIGL – Research Report), Fisher & Paykel Healthcare Corporation Limited (FSPKF – Research Report) and Viridian Therapeutics (VRDN – Research Report). Confident Investing Starts Here: Vigil Neuroscience Inc (VIGL) In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Vigil Neuroscience Inc, with a price target of $11.00. The company's shares closed last Friday at $7.89. According to Matteis is a 3-star analyst with an average return of 1.2% and a 40.9% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Neumora Therapeutics, Inc., Sionna Therapeutics, Inc., and KalVista Pharmaceuticals. Vigil Neuroscience Inc has an analyst consensus of Hold, with a price target consensus of $9.50. Fisher & Paykel Healthcare Corporation Limited received a Hold rating and a A$35.80 price target from Jefferies analyst Vanessa Thomson on May 23. The company's shares closed last Thursday at $20.70. Thomson has an average return of 22.2% when recommending Fisher & Paykel Healthcare Corporation Limited. According to Thomson is ranked #1098 out of 9562 analysts. Currently, the analyst consensus on Fisher & Paykel Healthcare Corporation Limited is a Moderate Buy with an average price target of $25.30. Viridian Therapeutics (VRDN) Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Viridian Therapeutics today and set a price target of $41.00. The company's shares closed last Friday at $13.57, close to its 52-week low of $11.40. According to CFA 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -5.8% and a 40.7% success rate. CFA covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Crinetics Pharmaceuticals, and Third Harmonic Bio, Inc. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viridian Therapeutics with a $38.80 average price target, representing a 189.8% upside. In a report issued on May 20, Wedbush also maintained a Buy rating on the stock with a $41.00 price target.
Business Insider
23-05-2025
- Business
- Business Insider
Vigil Neuroscience Inc (VIGL) was downgraded to a Hold Rating at Mizuho Securities
Mizuho Securities analyst Graig Suvannavejh downgraded Vigil Neuroscience Inc (VIGL – Research Report) to a Hold yesterday and set a price target of $8.00. The company's shares closed yesterday at $7.88. Confident Investing Starts Here: According to TipRanks, Suvannavejh is an analyst with an average return of -11.9% and a 36.02% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Apellis Pharmaceuticals, and Harmony Biosciences Holdings. In addition to Mizuho Securities, Vigil Neuroscience Inc also received a Hold from William Blair's Myles Minter in a report issued yesterday. However, on the same day, Stifel Nicolaus maintained a Buy rating on Vigil Neuroscience Inc (NASDAQ: VIGL).
